Catalyst Pharmaceuticals, Inc.(CPRX)Earnings, Financials & Key RatiosCatalyst Pharmaceuticals, Inc. (CPRX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company exhibits strong profitability and a pristine balance sheet with $755.9M in cash, the deceleration in revenue growth to 5.6% and inherent orphan drug regulatory risks warrant a cautious valuation approach at a 16.13 forward P/E.
Catalyst Pharmaceuticals, Inc. (CPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Catalyst Pharmaceuticals, Inc. (CPRX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.74vs $0.64+15.6% | $149Mvs $150M-0.1% |
| Q1 2026 | Feb 25, 2026 | $0.68vs $0.42+61.9% | $153Mvs $143M+6.8% |
| Q4 2025 | Nov 5, 2025 | $0.68vs $0.51+33.3% | $148Mvs $143M+4.0% |
| Q3 2025 | Aug 6, 2025 | $0.68vs $0.58+17.2% | $147Mvs $140M+4.4% |
Recent stock market news and headlines for Catalyst Pharmaceuticals, Inc. (CPRX)
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Key metrics vs top competitors for Catalyst Pharmaceuticals, Inc. (CPRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $31.49 | $3.85B | 18.74 | 19.78% | 36.39% | 25.49% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $545.36 | $12.57B | -42.44 | 432.05% | -27.32% | -50.15% | — |
Catalyst Pharmaceuticals, Inc. (CPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Catalyst Pharmaceuticals, Inc. (CPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
May 7, 2026·SEC
Mar 18, 2026·SEC
Get notified when CPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Catalyst Pharmaceuticals, Inc. (CPRX) stock FAQ — growth, dividends, profitability & financials explained
Catalyst Pharmaceuticals, Inc. (CPRX) reported $597.0M in revenue for fiscal year 2025.
Catalyst Pharmaceuticals, Inc. (CPRX) grew revenue by 19.8% over the past year. This is strong growth.
Yes, Catalyst Pharmaceuticals, Inc. (CPRX) is profitable, generating $221.3M in net income for fiscal year 2025 (36.4% net margin).
Catalyst Pharmaceuticals, Inc. (CPRX) has a return on equity (ROE) of 25.5%. This is excellent, indicating efficient use of shareholder capital.
Catalyst Pharmaceuticals, Inc. (CPRX) generated $208.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
